Opthea to have significant presence at the 24th EURETINA congress and EURETINA Innovation Spotlight Join us for presentations by retina thought leaders featuring sozinibercept’s mechanism of action, the design of the on-going Phase 3 trials, as well as further insights into previously presented data on superior visual gains in wet AMD patients highlighting sozinibercept’s potential to deliver superior efficacy beyond current standard-of-care anti-VEGF-A treatments. To read full press release: https://lnkd.in/ewQJsqpn Visit our booth at: F5 #Opthea #maculardegeneration #AMDResearch #wetAMD #ophthalmology #medicaleducation #biopharma #eyehealth #retinaspecialists #sozinibercept
Opthea
Biotechnology Research
South Yarra, VIC 5,669 followers
Opthea is committed to improving vision in patients suffering with retinal eye diseases.
About us
Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Opthea’s lead product candidate, sozinibercept, is being evaluated in two pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in combination with standard-of-care anti-VEGF-A monotherapies to improve overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents. To learn more, visit our website and follow us on X and LinkedIn. Enquiries can be directed to: [email protected]
- Website
-
http://www.opthea.com/
External link for Opthea
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- South Yarra, VIC
- Type
- Public Company
- Founded
- 2012
- Specialties
- Ophthalmological drug development, Retinal Disease, Ophthalmology, and Wet AMD
Locations
-
Primary
Suite 0403, Level 4, 650 Chapel Street
Toorak
South Yarra, VIC 3141, AU
-
Princeton, New Jersey 08540, US
Employees at Opthea
Updates
-
Opthea to participate in the Retina Society 57th Annual Scientific Meeting We look forward to seeing you at the Opthea booth #8 at the Retina Society 57th Annual Scientific Meeting in Lisbon, September 11-15, 2024. #Opthea #maculardegeneration #AMDResearch #wetAMD #ophthalmology #medicaleducation #biopharma #eyehealth #retinaspecialists #sozinibercept
-
Opthea reposted this
https://lnkd.in/g8YMywUR I wanted to share a personal note about Judy J. Robertson who will be stepping aside from her role as Chief Commercial Officer of Opthea on September 9, 2024. Judy is known for her passion and dedication to do the right thing for patients and for her tireless outreach to the medical community to connect and listen to thought leaders around the world. She didn’t miss an opportunity to tell the Opthea story, share our Phase 2b data and engage in deep conversations about the opportunities superior vision could represent to wet AMD patients and their families. For her, Opthea was personal, not a job. And we all could feel it in the energy she brings to a conversation or when she enters a room. With the appointment of Mike Campbell as her successor, Judy can now step aside from her role, enabling her to pursue other Board opportunities. She had served as a member of Opthea’s Board of Directors for seven months before stepping off to assist with the pre-commercialization plans for sozinibercept. During her tenure as Chief Commercial Officer, Judy laid the foundation for the anticipated commercialization of sozinibercept in wet AMD by preparing the launch plan, driving awareness of sozinibercept’s benefits with the retinal community and coordinating commercial pre-launch activities. And as I said, she did it with incredible passion and personal dedication. I truly appreciate what Judy has done for our Company and our team. And I am grateful that she will stay on until the full transition of critical projects to Mike has been completed. A heartfelt thank you from me personally and the entire Opthea team. I know Judy will go off and do great things, as you did for Opthea. #leadership #wetAMD #sozinibercept
-
Opthea Announces Executive Leadership Changes and Senior Hires Opthea today announced executive leadership changes in Finance and Commercial as well as senior hires for Biometrics, Clinical Operations and Market Access. These organizational changes further deepen the company’s expertise in retina, expand its clinical capabilities, while advancing Opthea’s commercial readiness, in anticipation of the Phase 3 topline data readout of sozinibercept in wet AMD in 2025. To read full press release: https://lnkd.in/e3pAqvvW #Opthea #maculardegeneration #AMDResearch #wetAMD #ophthalmology #medicaleducation #biopharma #eyehealth #retinaspecialists #sozinibercept
-
Interesting read about bringing a personal touch to patient care and providing eligible patients with access to cutting-edge advancements with the chance for better visual outcomes. https://lnkd.in/gYKiWesq #Opthea #maculardegeneration #AMDResearch #wetAMD #ophthalmology #medicaleducation #biopharma #eyehealth #retinaspecialists #sozinibercept Eyes On Eyecare
Expanding Treatment Options For Retinal Disease: Is A Change In Standard Of Care On The Horizon?
eyesoneyecare.com
-
Frederic Guerard, PharmD, CEO Opthea, will present at the H.C. Wainwright 26th Global Investment Conference on September 9, 2024, and the Cantor 2024 Global Healthcare Conference on September 17, 2024. Management will participate in one-on-one investor meetings at both conferences. To read the press release: https://lnkd.in/euXm698B #Opthea #maculardegeneration #AMDResearch #wetAMD #ophthalmology #medicaleducation #biopharma #eyehealth #retinaspecialists #sozinibercept
-
Opthea today announced financial results for the twelve months ended June 30, 2024, and highlighted recent corporate and clinical updates. To read full press release: https://lnkd.in/gyPhZixE To access Opthea’s annual report: https://lnkd.in/gMFhqSCr #Opthea #maculardegeneration #AMDResearch #wetAMD #ophthalmology #medicaleducation #biopharma #eyehealth #retinaspecialists #sozinibercept
-
Frederic Guerard, PharmD, CEO Opthea, will present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference and participate in one-on-one investor meetings on August 15, 2024. The webcast will be accessible both via the link: https://lnkd.in/epYYv5Cy and on the “Events & Presentations” section of Opthea’s website at http://ir.opthea.com/. #Opthea #maculardegeneration #AMDResearch #wetAMD #ophthalmology #medicaleducation #biopharma #eyehealth #retinaspecialists #sozinibercept
-
Opthea will present at the PEAK Monsoon Biotech Showcase event in Melbourne, Australia, on August 21, 2024. Dr. Megan Baldwin, Founder, CIO and Executive Director, Opthea, will showcase the Company’s pipeline and business case as one of eight leading biotech companies in Australia. Click here to register and find out more: https://peak.contact #Opthea #maculardegeneration #AMDResearch #wetAMD #ophthalmology #medicaleducation #biopharma #eyehealth #retinaspecialists #sozinibercept #BiotechShowcase
-
This story is a great summary of the most recent Opthea highlights. A big thank you to the editors of Eyes On Eyecare for sharing this article. https://lnkd.in/eQuwN8PD #Opthea #maculardegeneration #AMDResearch #wetAMD #ophthalmology #medicaleducation #biopharma #eyehealth #retinaspecialists #sozinibercept Eyes On Eyecare
Opthea selects global retinal leaders for Medical Advisory Board
glance.eyesoneyecare.com